Safety and efficacy of topical cidofovir to treat high-grade perianal and vulvar intraepithelial neoplasia in HIV-positive men and women
- 20 February 2013
- journal article
- research article
- Published by Wolters Kluwer Health in AIDS
- Vol. 27 (4) , 545-551
Abstract
Objective: To evaluate the safety and efficacy of topical cidofovir for treatment of high-grade squamous perianal intraepithelial neoplasia (PAIN) and vulvar intraepithelial neoplasia (VIN) lesions in HIV-positive individuals. Design: Phase IIa prospective multicenter trial conducted at eight clinical sites through the AIDS Malignancy Consortium. Methods: HIV-positive patients with biopsy-proven high-grade PAIN that was at least 3 cm2 were enrolled. PAIN biopsy specimens were assessed for human papillomavirus (HPV) using PCR and type-specific HPV probing. Participants applied 1% topical cidofovir to PAIN and VIN (if present) for six 2-week cycles. Results were designated as complete response (CR), partial response (PR) (>50% reduction in size), stable disease, or progressive disease (PD). Results: Twenty-four men and nine women (eight with high-grade VIN as well) were enrolled. Mean age was 44 years and mean CD4+ cell count was 412 cells/μl. HPV DNA (most commonly HPV16) was detected in all pretreatment study specimens. Twenty six (79%) participants completed treatment per protocol: CR, five (15%); PR, 12 (36%), stable disease, seven (21%); PD, two (6%) (one with a superficially invasive cancer and one with new area of high-grade PAIN). Treatment was well tolerated with most common adverse events being mild to moderate affecting lesional skin: pain/burning/irritation (25 patients) and ulceration (13 patients). Conclusion: Topical cidofovir had 51% efficacy in the short-term treatment of high-grade PAIN and VIN with acceptable toxicity in HIV-positive individuals. Randomized control studies with more prolonged treatment courses and longer follow-up to assess the durability of the response are needed.Keywords
This publication has 31 references indexed in Scilit:
- Proceedings of the 2012 ASCCP Biennial Scientific Meeting Oral and Poster Abstract PresentationsJournal of Lower Genital Tract Disease, 2012
- Treatment of Multifocal Bowen's Disease in Immunocompromised Women With Surgery and Topical ImiquimodObstetrics & Gynecology, 2012
- Neoplasms of Anal Canal and Perianal SkinClinics in Colon and Rectal Surgery, 2011
- Topical 5-fluorouracil treatment of anal intraepithelial neoplasia in human immunodeficiency virus-positive menBritish Journal of Dermatology, 2010
- A double-blind, randomized controlled trial of the use of imiquimod cream for the treatment of anal canal high-grade anal intraepithelial neoplasia in HIV-positive MSM on HAART, with long-term follow-up data including the use of open-label imiquimodAIDS, 2010
- Initiating patients on antiretroviral therapy at CD4 cell counts above 200 cells/μl is associated with improved treatment outcomes in South AfricaAIDS, 2010
- Risk of Human Papillomavirus–Associated Cancers Among Persons With AIDSJNCI: Journal of the National Cancer Institute, 2009
- Cidofovir induces an increase in levels of low‐risk and high‐risk HPV E6Head & Neck, 2009
- Imiquimod Leads to a Decrease of Human Papillomavirus DNA and to a Sustained Clearance of Anal Intraepithelial Neoplasia in HIV-Infected MenJournal of Investigative Dermatology, 2008
- Resolution of recurrent perianal condylomata acuminata by topical cidofovir in patients with HIV infectionJournal of the European Academy of Dermatology and Venereology, 2001